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Introduction 
Reactive amyloidosis is a disorder characterized by the 
deposition of amyloid A (AA) in multiple organs (1). The 
acute phase reactant, serum amyloid A (SAA); is the pre- 
cursor of the AA protein, and a chronic rise in SAA is 
required for the formation of this type of amyloid (2). In 
general, the underlying diseases leading to high levels of 
SAA and to AA protein deposition are of four categories: 
chronic infections, chronic inflammatory diseases, heredi- 
tary diseases and malignancies (1). Reactive amyloidosis 
was found to be associated with Mycobacteuium tuberculosis 
(3,4), but only rarely with non-tuberculous mycobacterial 
infection (5). The case report describes a patient who devel- 
oped reactive amyloidosis during chronic pulmonary in- 
fection with Mycobacterium simiae, a non-tuberculous 
mycobacterium, hitherto not related to this condition. 
Case Report 
A 73-year-old white male was admitted to the hospital 
because of fever, productive cough and weight loss of 
several weeks duration. His past medical history was sig- 
nificant for chronic obstructive lung disease and emphy- 
sema, associated with a long history of smoking. The chest 
radiogram and computed tomography (CT) revealed a 
large infiltrate with cavitation in the left lower lobe and 
hyperinflation in the other lung fields. The purified protein 
derivative (PPD) skin test (5 TU): which was positive in the 
past, became anergic. The white cell count was 14.45 x lo9 
cells 1 - I, the erythrocyte sedimentation rate (ESR) 100 mm 
h - ’ and the serum albumin 29 g 1 - I. The haemoglobin, 
platelet count, electrolytes, urinalysis, and renal and hepatic 
function tests were normal. The blood cultures were sterile. 
Acid-fast bacilli were seen in his sputum and gastric fluid, 
and were later identified as M simiae, susceptible to 
ethambutol and streptomycin. The identification of the 
mycobacterium species was based on its growth on 
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Loewenstein-Jense and Bactec 12B media, and on the 
results of niacin test, thermostability of catalase and tween 
hydrolysis studies. The patient was discharged from the 
hospital with antituberculous therapy, consisting of 
rifampicin, ethambutol and isoniazid. Improvement of the 
respiratory complaints and the radiological findings were 
noted in a follow-up examination, but 6 months after 
discharge, the patient discontinued treatment because of 
gastrointestinal side-effects and was lost to follow-up. 
The patient was re-admitted 2 years after cessation of 
therapy, because of epigastric pain, progressive weight loss 
and increasing weakness of several months duration. He 
had no symptoms suggesting congestive heart failure, nor 
has he suffered diarrhoea. He was cachectic and had 
epigastric tenderness. Bronchial breathing and rales were 
heard over his left lung base. The examination was other- 
wise unremarkable. The chest radiogram and CT scan 
revealed large cavitation in the left lower obe, widespread 
fibrosis and volume loss in the left lung and nodular 
infiltrates in the right lung. The creatinine was 380pmol 
1 - ’ haemoglobin 126 g l- ‘, ESR 100 mm h - ’ and urine 
protein l-5 g day-‘. Mycobacterium sijniae was isolated 
again from the sputum and gastric fluid. Treatment with the 
previous triple therapy was re-instituted. However, the 
patient did not tolerate any of these medications, continued 
to deteriorate and died of his lung disease and renal failure. 
The post mortem examination disclosed, in the lung, 
large areas of caseating necrosis, surrounded by fibrotic 
tissue: and numerous granulomas with a small number of 
multinucleated cells. The hilar lymph nodes had compar- 
able pathology. Lung areas unaffected by the disease were 
emphysematous with areas of atelectasis. Ziehl-Neelsen’s 
staining was negative, but M simiae were cultured from the 
necrotic tissues. The kidneys had no signs of chronic or 
acute mycobacterial infection. 
The gastrointestinal tract, kidneys, adrenals, spleen and 
heart contained hyaline deposits within the interstitium and 
blood vessel walls which were Congo red positive and their 
red colour became apple green under polarized light. 
Immunofluorescence staining of sections from amyloid- 
containing tissues showed that the amyloid deposits reacted 
with anti-AA antibody (Monoclonal mouse anti human 
amyloid A component, Code # M759, Dako, Glostrup, 
Denmark), and not with various preparations of antibodies 
against human kappa or lambda light chains. Using a 
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PLATE 1. SDS-PAGE (17% gel) of tissue extracts obtained 
by Shtrasburg method (6) demonstrates amyloid in the 
adrenal gland (lane 3) and kidney (lane 4). References are 
human apo-SAA (lower band, of 12 kDa, in lane 1) and 
purified human AA protein (8.5 kDa band, lane 2), both 
kindly donated by Dr B. Kaplan, Sheba Medical Center. 
unique feature of AA, not present in other amyloid pro- 
teins, to retain its electrophoretic and immunologic proper- 
ties despite formalin fixation (6) extracts were obtained 
from formalin-fixed, paraffin-embedded samples of amyloi- 
dotic tissues, and subjected to SDS-polyacrylamide gel 
electrophoresis. A band, comigrating with the AA marker, 
was identified for each sample (Plate 1). This finding further 
confirmed that the amyloid of the patient presented is of the 
AA type. 
Discussion 
Mycobactevium simiae was isolated in 1965 from monkeys, 
and in 1971 from man (7). Although usually not pathogenic 
in man, it may cause pneumonia, pulmonary cavitary 
lesions and disseminated disease in elderly patients with 
chronic pulmonary disease and lung malignancy and in 
immunocompromised hosts (7-9). 
Histologically, the lung lesion consists of caseating 
granulomas with Langerhans’ giant cells. Acid-fast bacilli 
were observed in the infected tissues (7). The organism is 
sensitive to cycloserine and ethionamide (7,10), but the use 
of these agents is limited because of significant side-effects. 
The commonly used antituberculous agents are less 
effective, but may contain the infection. 
The patient presented seemed to respond to the treatment 
with conservative antituberculous drugs. However, due to 
low compliance related to gastrointestinal side-effects, 
chronic lung infection was established and secondary sys- 
temic amyloidosis ensued, leading to death due to both 
pulmonary and renal failure. Although widespread depo- 
sition of amyloid occurred, only kidney involvement was 
clinically manifested. This clinical pathological dissociation 
is the rule in most cases of reactive amyloidosis. 
Secondary amyloidosis occurs in a variety of chronic 
infections. It has been described with M tuberculosis infec- 
tion (3), and from the non-tuberculous mycobacteria it has 
been reported only in patients with M. scrofulaceum infec- 
tion (5). Other chronic lung infections associated with the 
development of amyloidosis include pulmonary abscesses 
and bronchiectasis (4). This report includes chronic 
M. simiae infection among other lung infections leading to 
reactive amyloidosis, and supports the aiming of therapeu- 
tic efforts at eradication of the disease in the affected 
individual. 
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